You just read:

Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union

News provided by

Sanofi

27 Jun, 2017, 06:45 BST